Overslaan en naar de inhoud gaan

2020

Press release

Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST®

Pharming Group N.V. announces that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.

Lees meer
Press release

Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market

Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with a proposed listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares of nominal value €0.01 each ("Ordinary Shares") on the Nasdaq Global Market ("Nasdaq").

Lees meer

Filter

Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren